ORIGINAL RESEARCH article
Front. Med.
Sec. Precision Medicine
This article is part of the Research TopicPrecision Medicine in Cardiovascular Remodeling: Bridging Pathogenesis to Personalized Therapeutic StrategiesView all 14 articles
Evaluation of the Real-World Safety of Eptifibatide in the Treatment of ARDS: Results of a Disproportionality Analysis of FAERS Data
Provisionally accepted
- 1Jinan Central Hospital, Jinan, China
- 2Shandong Provincial Third Hospital, Jinan, China
- 3Shandong Second Provincial General Hospital, Jinan, China
- 4Shandong Provincial Corps Hospital of the Chinese People's Armed Police Force, Jinan, China
- 5Lijin County Hospital of Traditional Chinese Medicine, Jinan, China
- 6Lijin Traditional Chinese Medicine Hospital, Dongying, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Acute respiratory distress syndrome (ARDS) is a clinical syndrome with an extremely high mortality rate, and antiplatelet therapy is an important treatment approach. Eptifibatide, a glycoprotein IIb/IIIa receptor inhibitor (GPI), is primarily used to treat acute coronary syndrome and non-venous thromboembolic pulmonary embolism, as well as for antiplatelet therapy in conditions such as ARDS and septic shock. With its increasing clinical application, understanding its safety profile in real-world settings is essential. This study evaluated the clinical safety of Eptifibatide by analyzing all adverse event reports in the FDA Adverse Event Reporting System (FAERS) where Eptifibatide was listed as the primary suspected drug since 2004. Analytical methods included the Bayesian Confidence Propagation Neural Network (BCPNN), the UK Medicines and Healthcare Products Regulatory Agency (MHRA) comprehensive standard method, the Multi-item Gamma Poisson Shrinker (MGPS), the Proportional Reporting Ratio (PRR), and the Reporting Odds Ratio (ROR). The study confirmed known adverse reactions of Eptifibatide, such as bleeding, intracranial hemorrhage, stroke, thrombocytopenia, allergic reactions, immunogenicity, and hypotension, which are also listed in the drug's prescribing information. Additionally, some previously unmentioned adverse reactions were identified, including acute myocardial infarction, cardiac arrest, nausea, hemorrhagic pancreatitis, chills, dyspnea, and vascular pseudoaneurysm. The study also highlighted the importance of early detection of adverse reactions to Eptifibatide. This research provides insights into both known and potential adverse reactions associated with Eptifibatide in real-world clinical use, offering additional safety information for clinicians when prescribing Eptifibatide for ARDS treatment.
Keywords: Adverse Reactions, ARDS, Disproportionality analysis, eptifibatide, FAERS
Received: 13 Dec 2025; Accepted: 09 Feb 2026.
Copyright: © 2026 Ji, Zhang, Wang, Zhao, Wang and Shang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Feng Ji
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.